Related Experiment Video

Updated: May 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe

Sheila A Doggrell1

  • 1Queensland University of Technology, School of Biomedical Sciences, Gardens Point Campus, Faculty of Health, Brisbane, GPO 2343, QLD 4001, Australia. sheila.doggrell@qut.edu.au

Expert Opinion on Pharmacotherapy
|June 26, 2012
PubMed

Insights

Simvastatin effectively lowers LDL cholesterol, reducing cardiovascular risk. Ezetimibe also lowers LDL cholesterol but lacks proven clinical benefits for atherosclerosis or cardiovascular outcomes, warranting its use mainly in clinical trials.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Hypercholesterolemia management primarily targets low-density lipoprotein (LDL) cholesterol reduction.
  • Despite lipid-modifying drugs, significant cardiovascular mortality and morbidity persist.
  • Hypercholesterolemia is a key driver of atherosclerosis and coronary heart disease.

Purpose of the Study:

  • To evaluate the clinical benefits of ezetimibe.
  • To review clinical trials involving simvastatin and ezetimibe, individually and in combination.

Main Methods:

  • Systematic review of clinical trials.
  • Analysis of studies on simvastatin monotherapy.
  • Assessment of ezetimibe monotherapy and combination therapy with simvastatin.

Main Results:

  • Simvastatin demonstrated significant LDL-cholesterol reduction, linked to slowed atherosclerosis and reduced cardiovascular events.
  • Ezetimibe, alone or with simvastatin, effectively lowers LDL-cholesterol.
  • Ezetimibe's impact on atherosclerosis progression and clinical cardiovascular outcomes remains unproven.

Conclusions:

  • While simvastatin offers established cardiovascular benefits, ezetimibe's clinical utility beyond LDL-lowering is not substantiated.
  • Current evidence suggests restricting ezetimibe use to clinical trials investigating hard endpoints.
  • Routine use of ezetimibe in clinical practice is not recommended until proven benefits are demonstrated.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...